Avadel Pharmaceuticals (AVDL) 10-Q 9 Nov 17 2017 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Nov. 02, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	AVADEL PHARMACEUTICALS PLC
Entity Central Index Key	1,012,477
Trading Symbol	AVDL
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		39,762,209

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues:
Product sales and services	$ 39,147	$ 31,340	$ 138,009	$ 104,858
License and research revenue	528	747	484	2,303
Total	39,675	32,087	138,493	107,161
Operating expenses:
Cost of products and services sold	3,790	2,844	12,253	10,657
Research and development expenses	8,095	8,143	22,093	21,135
Selling, general and administrative expenses	11,563	12,740	35,804	33,491
Intangible asset amortization	564	3,702	1,692	10,918
(Gain)/loss - changes in fair value of related party contingent consideration	(9,906)	20,848	(30,107)	52,989
Restructuring (income) costs	(549)	0	3,173	0
Total operating expenses	13,557	48,277	44,908	129,190
Operating income (loss)	26,118	(16,190)	93,585	(22,029)
Investment income, net	1,110	490	2,689	1,080
Interest expense, net	(263)	(264)	(789)	(702)
Other income (expense) - changes in fair value of related party payable	768	(1,828)	2,988	(6,135)
Foreign exchange gain (loss)	(133)	1,249	(127)	(12)
Income (loss) before income taxes	27,600	(16,543)	98,346	(27,798)
Income tax provision	5,921	3,451	21,830	18,212
Net income (loss)	$ 21,679	$ (19,994)	$ 76,516	$ (46,010)
Net income (loss) per share - basic (in dollars per share)	$ 0.54	$ (0.48)	$ 1.87	$ (1.12)
Net income (loss) per share - diluted (in dollars per share)	$ 0.52	$ (0.48)	$ 1.81	$ (1.12)
Weighted average number of shares outstanding - basic (in shares)	40,061	41,241	40,839	41,241
Weighted average number of shares outstanding - diluted (in shares)	41,339	41,241	42,194	41,241

UNAUDITED CONDENSED CONSOLIDAT3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Other Comprehensive Income (Loss), Tax [Abstract]
Net income (loss)	$ 21,679	$ (19,994)	$ 76,516	$ (46,010)
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)	(229)	1,567	18	3,927
Net other comprehensive income (loss), net of $92, $152, $0 and ($49) tax, respectively	(512)	(2,405)	126	(958)
Total other comprehensive income (loss), net of tax	(741)	(838)	144	2,969
Total comprehensive income (loss)	$ 20,938	$ (20,832)	$ 76,660	$ (43,041)

UNAUDITED CONDENSED CONSOLIDAT4

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
Other comprehensive income, tax	$ 92	$ 152	$ 0	$ (49)

UNAUDITED CONDENSED CONSOLIDAT5

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 37,449	$ 39,215
Marketable securities	78,161	114,980
Accounts receivable	24,080	17,839
Inventories, net	5,870	3,258
Prepaid expenses and other current assets	3,373	5,894
Total current assets	148,933	181,186
Property and equipment, net	3,180	3,320
Goodwill	18,491	18,491
Intangible assets, net	94,256	22,837
Research and development tax credit receivable	3,547	1,775
Income tax deferred charge	0	10,342
Other	9,020	7,531
Total assets	277,427	245,482
Current liabilities:
Current portion of long-term debt	301	268
Current portion of long-term related party payable	30,986	34,177
Accounts payable	8,564	7,105
Deferred revenue	1,927	2,223
Accrued expenses	47,997	17,222
Income taxes	7,026	1,200
Other	507	226
Total current liabilities	97,308	62,421
Long-term debt, less current portion	614	547
Long-term related party payable, less current portion	76,131	135,170
Other	6,911	5,275
Total liabilities	180,964	203,413
Shareholders' equity:
Preferred shares, $0.01 nominal value; 50,000 shares authorized; none issued or outstanding at September 30, 2017 and December 31, 2016, respectively	0	0
Ordinary shares, nominal value of $0.01; 500,000 shares authorized; 41,435 and 41,371 issued and outstanding at September 30, 2017 and December 31, 2016, respectively	414	414
Treasury shares, at cost, 1,673 and 0 shares held at September 30, 2017 and December 31, 2016, respectively	(17,506)	0
Additional paid-in capital	391,416	385,020
Accumulated deficit	(254,440)	(319,800)
Accumulated other comprehensive loss	(23,421)	(23,565)
Total shareholders' equity	96,463	42,069
Total liabilities and shareholders' equity	$ 277,427	$ 245,482

UNAUDITED CONDENSED CONSOLIDAT6

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)	Sep. 30, 2017$ / sharesshares	Dec. 31, 2016$ / sharesshares
Statement of Financial Position [Abstract]
Preferred shares, nominal value (in usd per share) | $ / shares	$ 0.01	$ 0.01
Preferred shares, shares authorized (in shares)	50,000,000	50,000,000
Preferred shares, shares issued (in shares)	0	0
Preferred shares, shares outstanding (in shares)	0	0
Ordinary shares, nominal value (in usd per share) | (per share)	$ 0.01	$ 0.01
Ordinary shares, shares authorized (in shares)	500,000,000	500,000,000
Ordinary shares, shares issued (in shares)	41,435,000	41,371,000
Ordinary shares, shares outstanding (in shares)	41,435,000	41,371,000
Treasury Stock, Shares	1,673,000	0

UNAUDITED CONDENSED CONSOLIDAT7

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Net income (loss)	$ 76,516	$ (46,010)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	2,664	11,555
Loss on disposal of property and equipment	0	110
Loss (gain) on sale of marketable securities	(550)	666
Foreign exchange loss	127	12
Grants recognized in research and development expenses	0	(70)
Remeasurement of related party acquisition-related contingent consideration	(30,107)	52,989
Remeasurement of related party financing-related contingent consideration	(2,988)	6,135
Change in deferred tax and income tax deferred charge	322	(5,680)
Stock-based compensation expense	6,019	10,541
Increase (decrease) in cash from:
Accounts receivable	(6,240)	(7,594)
Inventories	(2,612)	2,080
Prepaid expenses and other current assets	1,924	671
Research and development tax credit receivable	(1,576)	(1,794)
Accounts payable & other current liabilities	804	1,291
Deferred revenue	(283)	(2,198)
Accrued expenses	9,324	2,700
Accrued income taxes	5,826	0
Earn-out payments for related party contingent consideration in excess of acquisition-date fair value	(24,729)	(14,486)
Royalty payments for related party payable in excess of original fair value	(3,446)	(1,790)
Other long-term assets and liabilities	(517)	2,032
Net cash provided by operating activities	30,478	11,160
Cash flows from investing activities:
Purchases of property and equipment	(533)	(1,000)
Acquisitions of businesses	0	628
Purchase of intangible assets	(52,139)	0
Proceeds from sales of marketable securities	153,398	46,483
Purchases of marketable securities	(115,893)	(96,199)
Net cash used in investing activities	(15,167)	(50,088)
Cash flows from financing activities:
Earn-out payments for related party contingent consideration	(961)	(6,834)
Royalty payments for related party payable	0	(1,117)
Reimbursement of loans	0	(61)
Cash proceeds from issuance of ordinary shares and warrants	376	0
Share repurchases	(16,707)	0
Net cash used in financing activities	(17,292)	(8,012)
Effect of foreign currency exchange rate changes on cash and cash equivalents	215	656
Net decrease in cash and cash equivalents	(1,766)	(46,284)
Cash and cash equivalents at January 1,	39,215	65,064
Cash and cash equivalents at September 30,	$ 37,449	$ 18,780

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Nature of Operations. Avadel Pharmaceuticals plc (“Avadel,” the “Company,” “we,” “our,” or “us”) is a specialty pharmaceutical company engaged in identifying, developing, and commercializing niche branded pharmaceutical products mainly in the U.S. Our business model consists of three distinct strategies: • the development of differentiated, patent protected products through application of the Company’s proprietary patented drug delivery platforms, Micropump® and LiquiTime®, that target high-value solid, liquid oral and alternative dosage forms through the U.S. Food and Drug Administration (FDA) 505(b)(2) approval process, which allows a sponsor to submit an application that doesn’t depend on efficacy, safety, and toxicity data created by the sponsor. In addition to Micropump® and LiquiTime®, the Company has two other proprietary drug delivery platforms, Medusa™ (hydrogel depot technology for use with large molecules and peptides) and Trigger Lock™ (controlled release of opioid analgesics with potential abuse deterrent properties). • the identification of Unapproved Marketed Drugs (“UMDs”), which are currently sold in the U.S., but unapproved by the FDA, and the pursuit of approval for these products via a 505(b)(2) New Drug Application (NDA). To date, the Company has received three drug approvals through this “unapproved-to-approved” strategy, including: Bloxiverz® (neostigmine methylsulfate injection), Vazculep® (phenylephrine hydrochloride injection) and Akovaz® (ephedrine sulfate injection). As a potential source of near-term revenue growth, Avadel is working on the development of a fourth product for potential NDA submission and seeks to identify additional product candidates for development with this strategy. • the acquisition of commercial and or late-stage products or businesses. On September 1, 2017, the Company entered into an Exclusive License and Assignment Agreement ("ELAA") with Serenity Pharmaceuticals, LLC. The ELAA grants the Company the sole right to commercialize and further develop Noctiva™ in the United States. Noctiva is a proprietary low-dose formulation of desmopressin acetate administered through a patent-protected intranasal delivery system. It is the first and only product approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of nocturia due to nocturnal polyuria. Additionally, the Company markets three branded pediatric-focused pharmaceutical products in the primary care space, and a 510(k) approved device all of which were purchased through the acquisition of FSC Laboratories and FSC Pediatrics ("FSC") on February 5, 2016. We will consider further acquisitions and the Company continues to look for assets that could fit strategically into our current or potential future commercial sales force. The Company was incorporated in Ireland on December 1, 2015 as a private limited company, and re-registered as an Irish public limited company on November 21, 2016. Our headquarters is in Dublin, Ireland and we have operations in St. Louis, Missouri, United States, and Lyon, France. The Company is the successor to Flamel Technologies S.A., a French société anonyme (“Flamel”), as the result of the merger of Flamel with and into the Company which was completed at 11:59:59 p.m., Central Europe Time, on December 31, 2016 (the “Merger”) pursuant to the agreement between Flamel and Avadel entitled Common Draft Terms of Cross-Border Merger dated as of June 29, 2016 (the “Merger Agreement”). Immediately prior to the Merger, the Company was a wholly owned subsidiary of Flamel. As a result of the Merger Agreement: • Flamel ceased to exist as a separate entity and the Company continued as the surviving entity and assumed all of the assets and liabilities of Flamel. • our authorized share capital is $5,500 divided into 500,000 ordinary shares with a nominal value of $0.01 each and 50,000 preferred shares with a nominal value of $0.01 each ◦ all outstanding ordinary shares of Flamel, €0.122 nominal value per share, were canceled and exchanged on a one-for-one basis for newly issued ordinary shares of the Company, $0.01 nominal value per share. This change in nominal value of our outstanding shares resulted in our reclassifying $5,937 on our balance sheet from ordinary shares to additional paid-in capital ◦ our Board of Directors is authorized to issue preferred shares on a non-pre-emptive basis, for a maximum period of five years, at which point it may be renewed by shareholders. The Board of Directors has discretion to dictate terms attached to the preferred shares, including voting, dividend, conversion rights, and priority relative to other classes of shares with respect to dividends and upon a liquidation. • all outstanding American Depositary Shares (ADSs) representing ordinary shares of Flamel were canceled and exchanged on a one-for-one basis for ADSs representing ordinary shares of the Company. Thus, the Merger changed the jurisdiction of our incorporation from France to Ireland, and an ordinary share of the Company held (either directly or represented by an ADS) immediately after the Merger continued to represent the same proportional interest in our equity owned by the holder of a share of Flamel immediately prior to the Merger. References in these condensed consolidated financial statements and the notes thereto to “Avadel,” the “Company,” “we,” "our," “us,” and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires. Prior to completion of the Merger, the Flamel ADSs were listed on the Nasdaq Global Market (“Nasdaq”) under the trading symbol “FLML”; and immediately after the Merger the Company’s ADSs were listed for and began trading on Nasdaq on January 3, 2017 under the trading symbol “AVDL.” Further details about the reincorporation, the Merger and the Merger Agreement are contained in our definitive proxy statement filed with the Securities and Exchange Commission on May 1, 2017, and within the 2016 Annual Report on Form 10-K. Under Irish law, the Company can only pay dividends and repurchase shares out of distributable reserves, as discussed further in the Company's proxy statement filed with the SEC as of July 5, 2016. Upon completion of the Merger, the Company did not have any distributable reserves. On February 15, 2017, the Company filed a petition with the High Court of Ireland seeking the court's confirmation of a reduction of the Company's share premium so that it can be treated as distributable reserves for the purposes of Irish law. On March 6, 2017, the High Court issued its order approving the reduction of the Company's share premium by $317,254 which can be treated as distributable reserves. Basis of Presentation. The Condensed Consolidated Balance Sheet as of December 31, 2016, which is primarily derived from the prior year 2016 audited consolidated financial statements, and the interim condensed consolidated financial statements presented herein, have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s 2016 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 28, 2017. The condensed consolidated financial statements include the accounts of the Company and subsidiaries, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the dates and periods presented. All material intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period. Foreign Currency Translation. The reporting currency of the Company and our wholly-owned subsidiaries is the U.S. dollar. Subsidiaries that do not use the U.S. dollar as their functional currency translate: • profit and loss accounts at the weighted average exchange rates during the reporting period, • assets and liabilities at period end exchange rates, and • shareholders' equity accounts at historical rates. Resulting translation gains and losses are included as a separate component of shareholders' equity in Accumulated Other Comprehensive Loss. Assets and liabilities, excluding available-for-sale marketable securities, denominated in a currency other than the subsidiary's functional currency are translated to the subsidiary's functional currency at period end exchange rates with resulting gains and losses recognized in the condensed consolidated statements of income (loss). Revenue. Revenue includes sales of pharmaceutical products, amortization of licensing fees, and, if any, milestone payments for R&D achievements. Product Sales and Services Revenue is generally realized or realizable and earned when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the seller’s price to the buyer is fixed or determinable, and collectability is reasonably assured. The Company records revenue from product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery to the customer and when the selling price is determinable. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of deductions in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, as well as future expectations for such products. For generic products and branded products sold in mature markets where the ultimate net selling price to customer is estimable, the Company recognizes revenues upon delivery to the wholesaler. For new product launches the Company recognizes revenue once sufficient data is available to determine product acceptance in the marketplace such that product returns may be estimated based on historical data and there is evidence of reorders and consideration is made of wholesaler inventory levels. As part of the third quarter 2016 launch of Akovaz, the Company determined that sufficient data was available to determine the ultimate net selling price to the customer and therefore recognized revenue upon delivery to our wholesaler customers. Prior to the second quarter 2016, the Company did not have sufficient historical data to estimate certain revenue deductions. As such, it could not accurately estimate the ultimate net selling price of our Éclat portfolio of products and as a result delayed revenue recognition until the wholesaler sold the product through to end customers. During the second quarter of 2016, the Company determined that it had sufficient evidence, history, data and internal controls to estimate the ultimate selling price of our products upon delivery to our customers, the wholesalers. Accordingly, we discontinued the sell through revenue approach and now recognize revenue once the product is shipped from our warehouse. License and Research Revenue The Company’s license and research revenues consist of fees and milestone payments. Non-refundable fees where we have continuing performance obligations are deferred and are recognized ratably over our projected performance period. We recognize milestone payments, which are typically related to regulatory, commercial or other achievements by us or our licensees and distributors, as revenues when the milestone is accomplished and collection is reasonably assured.

Newly Issued Accounting Pronoun

Newly Issued Accounting Pronouncements	9 Months Ended
	Sep. 30, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Newly Issued Accounting Pronouncements	Newly Issued Accounting Pronouncements In March 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2017-07, " Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Costs. " The standard requires the service component of pension and other postretirement benefit expense to be presented in the same statement of income lines as other employee compensation costs, however, the other components will be presented outside of operating income. In addition, only the service cost component will be eligible for capitalization in assets. The standard is effective starting in 2018, with early adoption permitted. Retrospective application is required for the guidance on the statement of income presentation. Prospective application is required for the guidance on the cost capitalization in assets. The Company does not believe this standard will materially impact our consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, " Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment." This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for the Company in the first quarter of fiscal 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will assess the timing of adoption and impact of this guidance to future impairment considerations. In January, 2017, the FASB issued ASU 2017-01, " Business Combinations (Topic 805): Clarifying the Definition of a Business ." This update provides a screen to determine whether or not a set of assets is a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set of assets is not a business. If the screen is not met, the amendments in this update (1) require that to be considered a business, a set of assets must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. This guidance is effective for the Company in the first quarter of fiscal 2018. Early adoption is permitted for transactions not previously reported in the Company's consolidated financial statements. In September, 2017 the Company entered into an ELAA to acquire from Serenity Pharmaceuticals, LLC intellectual property rights to further develop and commercialize Noctiva in the United States. The Company elected to early adopt ASU 2017-01 and determined the intangible assets acquired as part of the ELAA should be accounted for as an acquisition of a single group of assets and not as a business combination. In October 2016, the FASB issued ASU 2016-16, " Income Taxes (Topic 740), Intra-Entity Transfers of Assets Other Than Inventory ," which requires companies to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. ASU 2016-16 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2017. The Company elected to early-adopt ASU 2016-16 on a modified-retrospective basis as of January 1, 2017. Adoption of ASU 2016-16 eliminated the $11,156 income tax deferred charge recorded within the consolidated balance sheet as of December 31, 2016 and such elimination is reflected as an adjustment to accumulated deficit as of January 1, 2017. In August 2016, the FASB issued ASU 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments ." ASU 2016-15 identifies how certain cash receipts and cash payments are presented and classified in the Statement of Cash Flows under Topic 230. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-15 should be applied retrospectively and early adoption is permitted, including adoption in an interim period. The Company does not believe this standard will materially impact our consolidated financial statements. In May 2014, the FASB issued ASU 2014-09 “ Revenue from Contracts with Customers ” which supersedes the most current revenue recognition requirements. This ASU requires entities to recognize revenue in a way that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. Through May 2016, the FASB issued ASU 2016-08 “ Principal versus Agent Considerations (Reporting Revenue Gross versus Net) ,” ASU 2016-10 “ Identifying Performance Obligations and Licensing, ” and ASU 2016-12, “ Narrow-Scope Improvements and Practical Expedients, ” which provide supplemental adoption guidance and clarification to ASU 2014-09, respectively. These ASUs will be effective for annual and interim periods beginning after December 15, 2017 with early adoption for annual and interim periods beginning after December 15, 2016 permitted and should be applied retrospectively to each prior reporting period presented or as a modified retrospective adjustment as of the date of adoption. The Company is currently evaluating this pronouncement to determine the impact of adoption on our consolidated financial statements, including which transition approach will be applied. The Company has decided not to early adopt the new pronouncement. The Company has assembled an implementation team consisting of a project manager as well as a cross functional project team responsible for assessing the impact the new revenue pronouncement will have on its consolidated financial statements and related disclosures. The implementation team is in the assessment phase, which consists of in depth analysis around the Company’s contracts and will result in a comparison of historical accounting policies and practices to the requirements of the new revenue pronouncement. The implementation team will then identify any potential changes to business processes, systems and controls necessary to support recognition and disclosure under the new revenue pronouncement. In February 2016, the FASB issued ASU 2016-02, “ Leases ” which supersedes ASC 840 “ Leases ” and creates a new topic, ASC 842 “ Leases .” This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with earlier application permitted. This update will be applied using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the effect of this update on our consolidated financial statements. In January 2016, the FASB issued ASU 2016-01, "Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ." The amendments in this update address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2017, and requires a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. Early adoption is not permitted. The new guidance will require the change in fair value of equity investments with readily determinable fair values to be recognized through the statement of income. We are currently evaluating the full impact of the standard; however, upon adoption, the change in the fair value of our available-for-sale equity investments will be recognized in our consolidated statement of income (loss) rather than as a component of our consolidated statement of comprehensive income (loss).

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively when accounting for and reporting certain financial instruments, when measuring certain contingent consideration liabilities and in the initial recognition of net assets acquired in a business combination. Fair value is estimated by applying the hierarchy described below, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: ASC 820, Fair Value Measurements and Disclosures defines fair value as a market-based measurement that should be determined based on the assumptions that marketplace participants would use in pricing an asset or liability. When estimating fair value, depending on the nature and complexity of the asset or liability, we may generally use one or each of the following techniques: • Income approach, which is based on the present value of a future stream of net cash flows. • Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities. As a basis for considering the assumptions used in these techniques, the standard establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows: • Level 1 - Quoted prices for identical assets or liabilities in active markets. • Level 2 - Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means. • Level 3 - Unobservable inputs that reflect estimates and assumptions. The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying consolidated balance sheets: As of September 30, 2017 As of December 31, 2016 Fair Value Measurements: Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Marketable securities (see Note 4) Equity securities $ 454 $ — $ — $ 4,033 $ — $ — Money market funds 44,312 — — — — — Corporate bonds — 18,986 — — 57,348 — Government securities - U.S. — 11,133 — — 42,814 — Government securities - Non-U.S. — 69 — — 233 — Other fixed-income securities — 3,207 — — 10,471 — Other securities — — — — 81 — Total assets $ 44,766 $ 33,395 $ — $ 4,033 $ 110,947 $ — Related party payables (see Note 7) — — 107,117 — — 169,347 Total liabilities $ — $ — $ 107,117 $ — $ — $ 169,347 A review of fair value hierarchy classifications is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. During the periods ended September 30, 2017 and December 31, 2016 , there were no transfers into and out of Level 1, 2, or 3. During the three and nine month periods ended September 30, 2017 and 2016 , we did not recognize any other-than-temporary impairment loss. Some of the Company's financial instruments, such as cash and cash equivalents, accounts receivable and accounts payable, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature. Additionally, the Company's long-term debt is reflected in the balance sheet at carrying value, which approximates fair value, as these represent non-interest bearing grants from the French government and are repayable only if the research project is technically or commercially successful.

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Marketable Securities The Company has investments in available-for-sale marketable securities which are recorded at fair market value. Unrealized gains and losses are recorded as other comprehensive income (loss) in shareholders’ equity, net of income tax effects. The following tables show the Company’s available-for-sale securities’ adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of September 30, 2017 and December 31, 2016 , respectively: As of September 30, 2017 Marketable Securities: Adjusted Cost Unrealized Gains Unrealized Losses Fair Value Equity securities $ 438 $ 26 $ (10 ) $ 454 Money market funds 44,311 1 — 44,312 Corporate bonds 19,014 84 (112 ) 18,986 Government securities - U.S. 11,220 21 (108 ) 11,133 Government securities - Non-U.S. 70 — (1 ) 69 Other fixed-income securities 3,212 — (5 ) 3,207 Total $ 78,265 $ 132 $ (236 ) $ 78,161 As of December 31, 2016 Marketable Securities: Adjusted Cost Unrealized Gains Unrealized Losses Fair Value Equity securities $ 3,689 $ 409 $ (65 ) $ 4,033 Corporate bonds 57,871 89 (612 ) 57,348 Government securities - U.S. 43,049 515 (750 ) 42,814 Government securities - Non-U.S. 247 — (14 ) 233 Other fixed-income securities 10,281 221 (31 ) 10,471 Other securities 81 — — 81 Total $ 115,218 $ 1,234 $ (1,472 ) $ 114,980 We determine realized gains or losses on the sale of marketable securities on a specific identification method. We recognized gross realized gains of $2,978 and $635 for the three months ended September 30, 2017 , and 2016 , respectively. These realized gains were offset by realized losses of $2,432 and $756 for the three months ended September 30, 2017 , and 2016 , respectively. We recognized gross realized gains of $4,228 and $709 for the nine months ended September 30, 2017 , and 2016 , respectively. These realized gains were offset by realized losses of $3,755 and $1,430 for the nine months ended September 30, 2017 , and 2016 , respectively. We reflect these gains and losses as a component of investment income in the accompanying condensed consolidated statements of income (loss). The following table summarizes the estimated fair value of our investments in marketable debt securities, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities as of September 30, 2017 : Maturities Marketable Debt Securities: Less than 1 Year 1-5 Years 5-10 Years Greater than 10 Years Total Corporate bonds 1,361 16,219 1,136 270 18,986 Government securities - U.S. 172 8,547 348 2,066 11,133 Government securities - Non-U.S. — — 69 — 69 Other fixed-income securities — 2,473 734 — 3,207 Total $ 1,533 $ 27,239 $ 2,287 $ 2,336 $ 33,395 The Company has classified our investment in available-for-sale marketable securities as current assets in the condensed consolidated balance sheets as the securities need to be available for use, if required, to fund current operations. There are no restrictions on the sale of any securities in our investment portfolio.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Inventories	Inventories The principal categories of inventories, net of reserves of $2,039 and $3,223 at September 30, 2017 and December 31, 2016 , respectively, are comprised of the following: Inventory: September 30, 2017 December 31, 2016 Finished goods $ 4,605 $ 2,429 Raw materials 1,265 829 Total $ 5,870 $ 3,258

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets The Company's amortizable and unamortizable intangible assets at September 30, 2017 and December 31, 2016 are as follows: As of September 30, 2017 As of December 31, 2016 Goodwill and Intangible Assets: Gross Value Accumulated Amortization Net Carrying Amount Gross Value Accumulated Amortization Net Carrying Amount Amortizable intangible assets: Acquired developed technology - Noctiva $ 73,111 $ — $ 73,111 $ — $ — $ — Acquired developed technology - Vazculep 12,061 (9,411 ) 2,650 12,061 (8,801 ) 3,260 Acquired product marketing rights 16,600 (1,854 ) 14,746 16,600 (1,019 ) 15,581 Acquired developed technology 4,300 (551 ) 3,749 4,300 (304 ) 3,996 Total amortizable intangible assets $ 106,072 $ (11,816 ) $ 94,256 $ 32,961 $ (10,124 ) $ 22,837 Unamortizable intangible assets: Goodwill $ 18,491 $ — $ 18,491 $ 18,491 $ — $ 18,491 Total unamortizable intangible assets $ 18,491 $ — $ 18,491 $ 18,491 $ — $ 18,491 The Company recorded amortization expense related to amortizable intangible assets of $564 and $3,702 for the three months ended September 30, 2017 and 2016 , respectively. The Company recorded amortization expense related to amortizable intangible assets of $1,692 and $10,918 for the nine months ended September 30, 2017 and 2016 , respectively. During the period, the Company acquired $ 73,111 in developed technology as part of the ELAA with Serenity Pharmaceuticals, LLC. The aggregate cost was composed of an upfront payment of $50,000 , an accrued payment of $20,000 due within one year, and $3,111 of transaction costs. The Company will amortize the developed technology over a 13 year period beginning October 1, 2017. Amortizable intangible assets are amortized over their estimated useful lives, which range from three to fifteen years. Estimated amortization of intangible assets for the next five years is as follows: Estimated Amortization Expense: Amount 2017 $ 3,664 2018 7,882 2019 7,882 2020 7,882 2021 7,067

Long-Term Related Party Payable

Long-Term Related Party Payable	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Long-Term Related Party Payable	Long-Term Related Party Payable Long-term related party payable and related activity are reported at fair value and consist of the following for the three months ended September 30, 2017 : Activity during the Three Months Ended September 30, 2017 Changes in Fair Value of Related Party Payable Long-Term Related Party Payable: Balance, June 30, 2017 Payments to Related Parties Operating Expense / (Income) Other Expense / (Income) Balance, September 30, 2017 Acquisition-related contingent consideration: Warrants - Éclat Pharmaceuticals (a) $ 10,400 $ — $ (2,173 ) $ — $ 8,227 Earn-out payments - Éclat Pharmaceuticals (b) 84,094 (8,214 ) (7,685 ) — 68,195 Royalty agreement - FSC (c) 8,010 (296 ) (48 ) — 7,666 Financing-related: Royalty agreement - Deerfield (d) 6,743 (784 ) — (520 ) 5,439 Royalty agreement - Broadfin (e) 3,212 (374 ) — (248 ) 2,590 Long-term liability - FSC (f) 15,000 — — — 15,000 Total related party payable 127,459 $ (9,668 ) $ (9,906 ) $ (768 ) 107,117 Less: Current portion (40,615 ) (30,986 ) Total long-term related party payable $ 86,844 $ 76,131 Long-term related party payable and related activity are reported at fair value and consist of the following for the nine months ended September 30, 2017 : Activity during the Nine Months Ended September 30, 2017 Changes in Fair Value of Related Party Payable Long-Term Related Party Payable: Balance, December 31, 2016 Payments to Related Parties Operating Expense / (Income) Other Expense / (Income) Balance, September 30, 2017 Acquisition-related contingent consideration: Warrants - Éclat Pharmaceuticals (a) $ 11,217 $ — $ (2,990 ) $ — $ 8,227 Earn-out payments - Éclat Pharmaceuticals (b) 121,377 (24,729 ) (28,453 ) — 68,195 Royalty agreement - FSC (c) 7,291 (961 ) 1,336 — 7,666 Financing-related: Royalty agreement - Deerfield (d) 9,794 (2,332 ) — (2,023 ) 5,439 Royalty agreement - Broadfin (e) 4,668 (1,113 ) — (965 ) 2,590 Long-term liability - FSC (f) 15,000 — — — 15,000 Total related party payable 169,347 $ (29,135 ) $ (30,107 ) $ (2,988 ) 107,117 Less: Current portion (34,177 ) (30,986 ) Total long-term related party payable $ 135,170 $ 76,131 (a) As part of the consideration for the Company’s acquisition of Éclat on March 13, 2012, the Company issued two warrants to a related party with a six -year term which allow for the purchase of a combined total of 3,300 ordinary shares of Avadel. One warrant is exercisable for 2,200 shares at an exercise price of $7.44 per share, and the other warrant is exercisable for 1,100 shares at an exercise price of $11.00 per share. The fair value of the warrants is estimated on a quarterly basis using a Black-Scholes option pricing model with the following assumptions as of September 30 : Assumptions for the Warrant Valuation: September 30, 2017 September 30, 2016 Stock price $ 10.50 $ 12.40 Weighted average exercise price per share 8.63 8.63 Expected term (years) 0.50 1.50 Expected volatility 40.30 % 58.40 % Risk-free interest rate 1.20 % 0.68 % Expected dividend yield — — These Black-Scholes fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. The fair value of the warrant consideration is most sensitive to movement in the Company’s share price and expected volatility at the balance sheet date. Expected term : The expected term of the options or warrants represents the period of time between the grant date and the time the options or warrants are either exercised or forfeited, including an estimate of future forfeitures for outstanding options or warrants. Given the limited historical data and the grant of stock options and warrants to a limited population, the simplified method has been used to calculate the expected life. Expected volatility : The expected volatility is calculated based on an average of the historical volatility of the Company's stock price. Risk-free interest rate : The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant and a maturity that approximates the expected term. Expected dividend yield : The Company has not distributed any dividends since our inception and has no plan to distribute dividends in the foreseeable future. At the closing date of the 2012 Éclat acquisition and at September 30, 2017 , it was uncertain as to whether the Company would ultimately fulfill our obligation under these warrants using Company shares or cash. Accordingly, pursuant to the guidance of ASC 480, the Company determined that these warrants should be classified as a liability. This classification as a liability was further supported by the Company’s determination, pursuant to the guidance of ASC 815-40-15-7(i), that these warrants could also not be considered as being indexed to the Company’s own stock, on the basis that the exercise price for the warrants is determined in U.S. dollars, although the functional currency of the Company at the closing date of the Éclat acquisition was the Euro. (b) In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by the Company’s CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity. (c) In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part included a commitment to pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years. (d) As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat products until December 31, 2024. In connection with such debt financing transaction, the Company granted Deerfield a security interest in the product registration rights of the Eclat products. (e) As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat products until December 31, 2024. (f) In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part consists of payments totaling $1,050 annually for five years with a final payment in January 2021 of $15,000 . Substantially all of FSC's, and its subsidiaries, assets are pledged as collateral under this agreement. At September 30, 2017 , the fair value of each related party payable listed in (b) through (e) above was estimated using a discounted cash flow model based on estimated and projected annual net revenues or gross profit, as appropriate, of each of the specified Éclat and FSC products using an appropriate risk-adjusted discount rate ranging from 15% to 22% . These fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. Subsequent changes in the fair value of the acquisition-related related party payables, resulting primarily from management’s revision of key assumptions, will be recorded in the consolidated statements of income (loss) in the line items entitled "Changes in fair value of related party contingent consideration" for items noted in (b) and (c) above and in "Other income (expense) - changes in fair value of related party payable" for items (d) and (e) above. See Note 1: Summary of Significant Accounting Policies under the caption Acquisition-related Contingent Consideration and Financing-related Royalty Agreements in Part II, Item 8 of the Company’s 2016 Annual Report on Form 10-K for more information on key assumptions used to determine the fair value of these liabilities. The Company has chosen to make a fair value election pursuant to ASC 825, “ Financial Instruments ” for our royalty agreements detailed in items (d) and (e) above. These financing-related liabilities are recorded at fair market value on the consolidated balance sheets and the periodic change in fair market value is recorded as a component of “Other expense – changes in fair value of related party payable” on the consolidated statements of income (loss). The following table summarizes changes to the related party payables, a recurring Level 3 measurement, for the nine -month periods ended September 30, 2017 and 2016 , respectively: Related Party Payable Rollforward: Balance Balance at December 31, 2015 $ 122,693 Additions (2) 22,695 Payment of related party payables (24,227 ) Fair value adjustments (1) 59,124 Balance at September 30, 2016 180,285 Balance at December 31, 2016 169,347 Payment of related party payable (29,135 ) Fair value adjustments (1) (33,095 ) Balance at September 30, 2017 $ 107,117 (1) Fair value adjustments are reported as Changes in fair value of related party contingent consideration and Other income (expense) - changes in fair value of related party payable in the Condensed Consolidated Statements of Income (Loss). (2) Relates to the acquisition of FSC. See items (c) and (f) above.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxe s The components of income (loss) before income taxes are as follows: Three Months Ended September 30, Nine Months Ended September 30, Income (Loss) Before Income Taxes: 2017 2016 2017 2016 Ireland $ (6,111 ) $ (3,485 ) $ 1,924 $ (17,413 ) United States 29,627 (6,814 ) 96,288 4,948 France 3,313 (6,244 ) (1,950 ) (15,333 ) Other 771 — 2,084 — Total income before income taxes $ 27,600 $ (16,543 ) $ 98,346 $ (27,798 ) The items accounting for the difference between the income tax provision computed at the statutory rate and the Company's effective tax rate are as follows: Three Months Ended September 30, Nine Months Ended September 30, Income Tax Rate Reconciliation: 2017 2016 2017 2016 Statutory tax rate 12.5 % 33.3 % 12.5 % 33.3 % International tax rates differential 24.9 % (3.6 )% 20.5 % (13.3 )% Valuation allowance on net operating loss (1.6 )% (2.0 )% 0.5 % (15.3 )% Nondeductible change in fair value of contingent consideration (12.8 )% (38.9 )% (10.9 )% (62.0 )% Other (1.6 )% (9.6 )% (0.3 )% (8.2 )% Effective income tax rate 21.4 % (20.8 )% 22.3 % (65.5 )% Income tax provision - at statutory tax rate $ 3,449 $ (5,509 ) $ 12,294 $ (9,257 ) International tax rates differential 6,861 591 20,120 3,706 Valuation allowance on net operating loss (438 ) 339 476 4,252 Nondeductible change in fair value of contingent consideration (3,521 ) 6,436 (10,751 ) 17,236 Other (430 ) 1,594 (309 ) 2,275 Income tax provision - at effective income tax rate $ 5,921 $ 3,451 $ 21,830 $ 18,212 In 2016, we changed our jurisdiction of incorporation from France to Ireland by merging with and into our wholly owned Irish subsidiary. Accordingly, beginning in the fourth quarter of 2016, the Company reports the Irish tax jurisdiction as our domestic jurisdiction. For periods prior to the fourth quarter of 2016, the French tax jurisdiction was the domestic jurisdiction. The income tax provision for the three months ended September 30, 2017 and 2016 was $5,921 and $3,451 , respectively. The increase in the income tax provision for the three months ended September 30, 2017 is primarily the result of increases in income in the United States, which was partially offset by a reduction in the amount of nondeductible contingent consideration. The income tax provision for the nine months ended September 30, 2017 and 2016 was $21,830 and $18,212 , respectively. The increase in the income tax provision for the nine months ended September 30, 2017 is primarily the result of increases in income in the United States and Ireland, which was partially offset by a reduction in the amount of nondeductible contingent consideration.

Other Assets and Liabilities

Other Assets and Liabilities	9 Months Ended
	Sep. 30, 2017
Other Liabilities Disclosure [Abstract]
Other Assets and Liabilities	Other Assets and Liabilities Various other assets and liabilities are summarized as follows: Prepaid Expenses and Other Current Assets: September 30, 2017 December 31, 2016 Valued-added tax recoverable $ 1,049 $ 736 Prepaid expenses 1,002 3,442 Advance to suppliers and other current assets 726 1,265 Income tax receivable 596 451 Total $ 3,373 $ 5,894 Other Non-Current Assets: September 30, 2017 December 31, 2016 Deferred tax assets $ 7,110 $ 7,432 Other 1,910 99 Total $ 9,020 $ 7,531 Accrued Expenses: September 30, 2017 December 31, 2016 Accrued compensation $ 3,456 $ 3,291 Accrued social charges 827 794 Accrued employee severance (see Note 10) 1,926 — Customer allowances 13,453 7,981 Accrued amounts due to contract research organization 1,472 1,764 Accrued ELAA payment 20,000 — Accrued CMO charges 2,380 936 Other 4,483 2,456 Total $ 47,997 $ 17,222 Other Non-Current Liabilities: September 30, 2017 December 31, 2016 Provision for retirement indemnity $ 2,137 $ 2,431 Customer allowances 1,883 905 Unrecognized tax benefits 2,456 1,565 Other 435 374 Total $ 6,911 $ 5,275

Restructuring Costs

Restructuring Costs	9 Months Ended
	Sep. 30, 2017
Restructuring and Related Activities [Abstract]
Restructuring Costs	Restructuring Costs During the first quarter of 2017, the Company announced a plan to reduce our workforce at our Lyon, France site by approximately 50% . This reduction is an effort to align the Company's cost structure with our ongoing and future planned projects. In July 2017, the Company completed negotiations with the works council and received approval from the French Labor Commission (DIRECCTE) to implement the plan. The reduction is substantially complete at the end of the third quarter. However, the Company expects to incur other cost of up to approximately $500 , which are likely to be recognized through the first half of 2018. Restructuring income of $549 and charges of $3,173 were recognized during the three and nine months ended September 30, 2017 . No similar amounts were recorded during the three and nine months ended September 30, 2016 . The restructuring income resulted from a retirement indemnity curtailment gain of $549 in the three months ended September 30, 2017 associated with the reduction of certain defined benefit retirement plan liabilities due to the reduction in force. The following table sets forth activities for the Company’s cost reduction plan obligations for the nine months ended September 30, 2017 . There were no restructuring related charges in the nine months ended September 30, 2016 : Severance Obligation: 2017 Balance of accrued costs at January 1, $ — Charges for employee severance, benefits and other 3,722 Payments (2,164 ) Foreign currency impact 368 Balance of accrued costs at September 30, $ 1,926 Total accrued employee severance in the Company’s condensed consolidated balance sheet at September 30, 2017 is included under current liabilities in “Accrued expenses.”

Net Income (Loss) Per Share

Net Income (Loss) Per Share	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income (Loss) Per Share Basic net income (loss) per share is calculated using the weighted average number of shares outstanding during each period. The diluted net income (loss) per share calculation includes the impact of dilutive equity compensation awards and contingent consideration warrants. A reconciliation of basic and diluted net income (loss) per share, together with the related shares outstanding in thousands is as follows: Three Months Ended September 30, Nine Months Ended September 30, Net Income (Loss) Per Share: 2017 2016 2017 2016 Net income (loss) $ 21,679 $ (19,994 ) $ 76,516 $ (46,010 ) Weighted average shares: Basic shares 40,061 41,241 40,839 41,241 Effect of dilutive securities—options and warrants outstanding 1,278 — 1,355 — Diluted shares 41,339 41,241 42,194 41,241 Net income (loss) per share - basic $ 0.54 $ (0.48 ) $ 1.87 $ (1.12 ) Net income (loss) per share - diluted $ 0.52 $ (0.48 ) $ 1.81 $ (1.12 ) Potential common shares of 5,008 and 6,860 were excluded from the calculation of weighted average shares for the three months ended September 30, 2017 and 2016 , respectively, because their effect was considered to be anti-dilutive. Potential common shares of 5,086 and 6,860 were excluded from the calculation of weighted average shares for the nine months ended September 30, 2017 and 2016 , respectively, because their effect was considered to be anti-dilutive.

Comprehensive Income (Loss)

Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2017
Stockholders' Equity Note [Abstract]
Comprehensive Income (Loss)	Comprehensive Income (Loss) The following table shows the components of accumulated other comprehensive loss for the three and nine months ended September 30, 2017 and 2016 , respectively, net of tax effects: Three Months Ended September 30, Nine Months Ended September 30, Accumulated Other Comprehensive Loss: 2017 2016 2017 2016 Foreign currency translation adjustment: Beginning balance $ (23,089 ) $ (19,952 ) $ (23,336 ) $ (22,312 ) Foreign currency translation gain (loss) (229 ) 1,567 18 3,927 Balance at September 30, $ (23,318 ) $ (18,385 ) $ (23,318 ) $ (18,385 ) Unrealized gain (loss) on marketable securities, net Beginning balance $ 409 $ 1,102 $ (229 ) $ (345 ) Net other comprehensive income (loss), net of $92, $152, $0 and ($49) tax, respectively (512 ) (2,405 ) 126 (958 ) Balance at September 30, $ (103 ) $ (1,303 ) $ (103 ) $ (1,303 ) Accumulated other comprehensive loss at September 30, $ (23,421 ) $ (19,688 ) $ (23,421 ) $ (19,688 ) The effect on the Company’s condensed consolidated financial statements of amounts reclassified out of accumulated other comprehensive loss was immaterial for all periods presented.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2017
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Shareholders’ Equity The following table presents a reconciliation of the Company’s beginning and ending balances in shareholders’ equity for the nine months ended September 30, 2017 : Shareholders' Equity: 2017 Shareholders' equity - January 1, $ 42,069 Net income 76,516 Adjustment to accumulated deficit (see Note 2) (11,156 ) Other comprehensive income 144 Stock option exercised 377 Stock-based compensation expense 6,019 Share repurchases (17,506 ) Shareholders' equity - September 30, $ 96,463 Share Repurchases In March 2017, the Board of Directors approved an authorization to repurchase up to $25,000 of Avadel ordinary shares represented by American Depositary Shares. Under this authorization, which has an indefinite duration, share repurchases may be made in the open market, in block transactions on or off the exchange, in privately negotiated transactions, or through other means as determined by the Board of Directors and in accordance with the regulations of the Securities and Exchange Commission. The timing and amount of repurchases, if any, will depend on a variety of factors, including the price of our shares, cash resources, alternative investment opportunities, corporate and regulatory requirements and market conditions. This share repurchase program may be modified, suspended or discontinued at any time without prior notice. We may also from time to time establish a trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934 to facilitate purchases of our shares under this program. As of September 30, 2017, the Company had repurchased 1,673 ordinary shares for $17,506 , of which $799 remained unsettled within accounts payable at September 30, 2017.

Company Operations by Product

Company Operations by Product	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Company Operations by Product	Company Operations by Product The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company's Chief Operating Decision Maker is the CEO. The CEO and the Board review profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the majority of the Company's products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment. The following table presents a summary of total revenues by these products: Three Months Ended September 30, Nine Months Ended September 30, Revenues by Product: 2017 2016 2017 2016 Bloxiverz $ 9,920 $ 15,591 $ 37,541 $ 65,958 Vazculep 9,573 9,340 29,906 29,167 Akovaz 18,561 5,568 65,110 5,568 Other 1,093 841 5,452 4,165 Total product sales and services 39,147 31,340 138,009 104,858 License and research revenue 528 747 484 2,303 Total revenues $ 39,675 $ 32,087 $ 138,493 $ 107,161

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Litigation The Company is subject to potential liabilities generally incidental to our business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including legal fees and expenses) will be incurred and such costs can be reasonably estimated. At September 30, 2017 and December 31, 2016 , there were no contingent liabilities with respect to any threat of litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company’s consolidated financial position, results of operations, cash flows or liquidity. Material Commitments The Company has a commitment to purchase finished product from a contract manufacturer for a six-year period commencing in 2018. Commitments for this arrangement, at maximum quantities and at contractual prices over the remaining life of the contract, and excluding any waived commitments, are as follows for the years ended December 31: Purchase Commitment: Balance 2018 $ 3,241 2019 3,704 2020 3,704 2021 3,704 2022 3,704 Thereafter 3,704 Total $ 21,761 Other than commitments disclosed in Note 14 - Contingent Liabilities and Commitments to the Company's consolidated financial statements included in Part II, Item 8 of the Company’s 2016 Annual Report on Form 10-K and those noted above, there were no other material commitments outside of the normal course of business. Material commitments in the normal course of business include long-term debt and post-retirement benefit plan obligations which are disclosed in Note 9 - Long-Term Debt and Note 12 – Post-Retirement Benefit Plans, respectively, to the Company's consolidated financial statements included in Part II, Item 8 of the Company’s 2016 Annual Report on Form 10-K and long-term contingent consideration payable as disclosed in Note 7 – Long-Term Related Party Payable, to the Company's condensed consolidated financial statements included in Part I, Item 1 of this report.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations. Avadel Pharmaceuticals plc (“Avadel,” the “Company,” “we,” “our,” or “us”) is a specialty pharmaceutical company engaged in identifying, developing, and commercializing niche branded pharmaceutical products mainly in the U.S. Our business model consists of three distinct strategies: • the development of differentiated, patent protected products through application of the Company’s proprietary patented drug delivery platforms, Micropump® and LiquiTime®, that target high-value solid, liquid oral and alternative dosage forms through the U.S. Food and Drug Administration (FDA) 505(b)(2) approval process, which allows a sponsor to submit an application that doesn’t depend on efficacy, safety, and toxicity data created by the sponsor. In addition to Micropump® and LiquiTime®, the Company has two other proprietary drug delivery platforms, Medusa™ (hydrogel depot technology for use with large molecules and peptides) and Trigger Lock™ (controlled release of opioid analgesics with potential abuse deterrent properties). • the identification of Unapproved Marketed Drugs (“UMDs”), which are currently sold in the U.S., but unapproved by the FDA, and the pursuit of approval for these products via a 505(b)(2) New Drug Application (NDA). To date, the Company has received three drug approvals through this “unapproved-to-approved” strategy, including: Bloxiverz® (neostigmine methylsulfate injection), Vazculep® (phenylephrine hydrochloride injection) and Akovaz® (ephedrine sulfate injection). As a potential source of near-term revenue growth, Avadel is working on the development of a fourth product for potential NDA submission and seeks to identify additional product candidates for development with this strategy. • the acquisition of commercial and or late-stage products or businesses. On September 1, 2017, the Company entered into an Exclusive License and Assignment Agreement ("ELAA") with Serenity Pharmaceuticals, LLC. The ELAA grants the Company the sole right to commercialize and further develop Noctiva™ in the United States. Noctiva is a proprietary low-dose formulation of desmopressin acetate administered through a patent-protected intranasal delivery system. It is the first and only product approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of nocturia due to nocturnal polyuria. Additionally, the Company markets three branded pediatric-focused pharmaceutical products in the primary care space, and a 510(k) approved device all of which were purchased through the acquisition of FSC Laboratories and FSC Pediatrics ("FSC") on February 5, 2016. We will consider further acquisitions and the Company continues to look for assets that could fit strategically into our current or potential future commercial sales force. The Company was incorporated in Ireland on December 1, 2015 as a private limited company, and re-registered as an Irish public limited company on November 21, 2016. Our headquarters is in Dublin, Ireland and we have operations in St. Louis, Missouri, United States, and Lyon, France. The Company is the successor to Flamel Technologies S.A., a French société anonyme (“Flamel”), as the result of the merger of Flamel with and into the Company which was completed at 11:59:59 p.m., Central Europe Time, on December 31, 2016 (the “Merger”) pursuant to the agreement between Flamel and Avadel entitled Common Draft Terms of Cross-Border Merger dated as of June 29, 2016 (the “Merger Agreement”). Immediately prior to the Merger, the Company was a wholly owned subsidiary of Flamel. As a result of the Merger Agreement: • Flamel ceased to exist as a separate entity and the Company continued as the surviving entity and assumed all of the assets and liabilities of Flamel. • our authorized share capital is $5,500 divided into 500,000 ordinary shares with a nominal value of $0.01 each and 50,000 preferred shares with a nominal value of $0.01 each ◦ all outstanding ordinary shares of Flamel, €0.122 nominal value per share, were canceled and exchanged on a one-for-one basis for newly issued ordinary shares of the Company, $0.01 nominal value per share. This change in nominal value of our outstanding shares resulted in our reclassifying $5,937 on our balance sheet from ordinary shares to additional paid-in capital ◦ our Board of Directors is authorized to issue preferred shares on a non-pre-emptive basis, for a maximum period of five years, at which point it may be renewed by shareholders. The Board of Directors has discretion to dictate terms attached to the preferred shares, including voting, dividend, conversion rights, and priority relative to other classes of shares with respect to dividends and upon a liquidation. • all outstanding American Depositary Shares (ADSs) representing ordinary shares of Flamel were canceled and exchanged on a one-for-one basis for ADSs representing ordinary shares of the Company. Thus, the Merger changed the jurisdiction of our incorporation from France to Ireland, and an ordinary share of the Company held (either directly or represented by an ADS) immediately after the Merger continued to represent the same proportional interest in our equity owned by the holder of a share of Flamel immediately prior to the Merger. References in these condensed consolidated financial statements and the notes thereto to “Avadel,” the “Company,” “we,” "our," “us,” and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires. Prior to completion of the Merger, the Flamel ADSs were listed on the Nasdaq Global Market (“Nasdaq”) under the trading symbol “FLML”; and immediately after the Merger the Company’s ADSs were listed for and began trading on Nasdaq on January 3, 2017 under the trading symbol “AVDL.” Further details about the reincorporation, the Merger and the Merger Agreement are contained in our definitive proxy statement filed with the Securities and Exchange Commission on May 1, 2017, and within the 2016 Annual Report on Form 10-K. Under Irish law, the Company can only pay dividends and repurchase shares out of distributable reserves, as discussed further in the Company's proxy statement filed with the SEC as of July 5, 2016. Upon completion of the Merger, the Company did not have any distributable reserves. On February 15, 2017, the Company filed a petition with the High Court of Ireland seeking the court's confirmation of a reduction of the Company's share premium so that it can be treated as distributable reserves for the purposes of Irish law. On March 6, 2017, the High Court issued its order approving the reduction of the Company's share premium by $317,254 which can be treated as distributable reserves.
Basis of Presentation	Basis of Presentation. The Condensed Consolidated Balance Sheet as of December 31, 2016, which is primarily derived from the prior year 2016 audited consolidated financial statements, and the interim condensed consolidated financial statements presented herein, have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s 2016 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 28, 2017. The condensed consolidated financial statements include the accounts of the Company and subsidiaries, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the dates and periods presented. All material intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.
Foreign Currency Translation	Foreign Currency Translation. The reporting currency of the Company and our wholly-owned subsidiaries is the U.S. dollar. Subsidiaries that do not use the U.S. dollar as their functional currency translate: • profit and loss accounts at the weighted average exchange rates during the reporting period, • assets and liabilities at period end exchange rates, and • shareholders' equity accounts at historical rates. Resulting translation gains and losses are included as a separate component of shareholders' equity in Accumulated Other Comprehensive Loss. Assets and liabilities, excluding available-for-sale marketable securities, denominated in a currency other than the subsidiary's functional currency are translated to the subsidiary's functional currency at period end exchange rates with resulting gains and losses recognized in the condensed consolidated statements of income (loss).
Revenue	Revenue. Revenue includes sales of pharmaceutical products, amortization of licensing fees, and, if any, milestone payments for R&D achievements. Product Sales and Services Revenue is generally realized or realizable and earned when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the seller’s price to the buyer is fixed or determinable, and collectability is reasonably assured. The Company records revenue from product sales when title and risk of ownership have been transferred to the customer, which is typically upon delivery to the customer and when the selling price is determinable. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of deductions in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, as well as future expectations for such products. For generic products and branded products sold in mature markets where the ultimate net selling price to customer is estimable, the Company recognizes revenues upon delivery to the wholesaler. For new product launches the Company recognizes revenue once sufficient data is available to determine product acceptance in the marketplace such that product returns may be estimated based on historical data and there is evidence of reorders and consideration is made of wholesaler inventory levels. As part of the third quarter 2016 launch of Akovaz, the Company determined that sufficient data was available to determine the ultimate net selling price to the customer and therefore recognized revenue upon delivery to our wholesaler customers. Prior to the second quarter 2016, the Company did not have sufficient historical data to estimate certain revenue deductions. As such, it could not accurately estimate the ultimate net selling price of our Éclat portfolio of products and as a result delayed revenue recognition until the wholesaler sold the product through to end customers. During the second quarter of 2016, the Company determined that it had sufficient evidence, history, data and internal controls to estimate the ultimate selling price of our products upon delivery to our customers, the wholesalers. Accordingly, we discontinued the sell through revenue approach and now recognize revenue once the product is shipped from our warehouse. License and Research Revenue The Company’s license and research revenues consist of fees and milestone payments. Non-refundable fees where we have continuing performance obligations are deferred and are recognized ratably over our projected performance period. We recognize milestone payments, which are typically related to regulatory, commercial or other achievements by us or our licensees and distributors, as revenues when the milestone is accomplished and collection is reasonably assured.
Newly Issued Accounting Pronouncements	Newly Issued Accounting Pronouncements In March 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2017-07, " Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Costs. " The standard requires the service component of pension and other postretirement benefit expense to be presented in the same statement of income lines as other employee compensation costs, however, the other components will be presented outside of operating income. In addition, only the service cost component will be eligible for capitalization in assets. The standard is effective starting in 2018, with early adoption permitted. Retrospective application is required for the guidance on the statement of income presentation. Prospective application is required for the guidance on the cost capitalization in assets. The Company does not believe this standard will materially impact our consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, " Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment." This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for the Company in the first quarter of fiscal 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will assess the timing of adoption and impact of this guidance to future impairment considerations. In January, 2017, the FASB issued ASU 2017-01, " Business Combinations (Topic 805): Clarifying the Definition of a Business ." This update provides a screen to determine whether or not a set of assets is a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set of assets is not a business. If the screen is not met, the amendments in this update (1) require that to be considered a business, a set of assets must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. This guidance is effective for the Company in the first quarter of fiscal 2018. Early adoption is permitted for transactions not previously reported in the Company's consolidated financial statements. In September, 2017 the Company entered into an ELAA to acquire from Serenity Pharmaceuticals, LLC intellectual property rights to further develop and commercialize Noctiva in the United States. The Company elected to early adopt ASU 2017-01 and determined the intangible assets acquired as part of the ELAA should be accounted for as an acquisition of a single group of assets and not as a business combination. In October 2016, the FASB issued ASU 2016-16, " Income Taxes (Topic 740), Intra-Entity Transfers of Assets Other Than Inventory ," which requires companies to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. ASU 2016-16 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2017. The Company elected to early-adopt ASU 2016-16 on a modified-retrospective basis as of January 1, 2017. Adoption of ASU 2016-16 eliminated the $11,156 income tax deferred charge recorded within the consolidated balance sheet as of December 31, 2016 and such elimination is reflected as an adjustment to accumulated deficit as of January 1, 2017. In August 2016, the FASB issued ASU 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments ." ASU 2016-15 identifies how certain cash receipts and cash payments are presented and classified in the Statement of Cash Flows under Topic 230. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-15 should be applied retrospectively and early adoption is permitted, including adoption in an interim period. The Company does not believe this standard will materially impact our consolidated financial statements. In May 2014, the FASB issued ASU 2014-09 “ Revenue from Contracts with Customers ” which supersedes the most current revenue recognition requirements. This ASU requires entities to recognize revenue in a way that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. Through May 2016, the FASB issued ASU 2016-08 “ Principal versus Agent Considerations (Reporting Revenue Gross versus Net) ,” ASU 2016-10 “ Identifying Performance Obligations and Licensing, ” and ASU 2016-12, “ Narrow-Scope Improvements and Practical Expedients, ” which provide supplemental adoption guidance and clarification to ASU 2014-09, respectively. These ASUs will be effective for annual and interim periods beginning after December 15, 2017 with early adoption for annual and interim periods beginning after December 15, 2016 permitted and should be applied retrospectively to each prior reporting period presented or as a modified retrospective adjustment as of the date of adoption. The Company is currently evaluating this pronouncement to determine the impact of adoption on our consolidated financial statements, including which transition approach will be applied. The Company has decided not to early adopt the new pronouncement. The Company has assembled an implementation team consisting of a project manager as well as a cross functional project team responsible for assessing the impact the new revenue pronouncement will have on its consolidated financial statements and related disclosures. The implementation team is in the assessment phase, which consists of in depth analysis around the Company’s contracts and will result in a comparison of historical accounting policies and practices to the requirements of the new revenue pronouncement. The implementation team will then identify any potential changes to business processes, systems and controls necessary to support recognition and disclosure under the new revenue pronouncement. In February 2016, the FASB issued ASU 2016-02, “ Leases ” which supersedes ASC 840 “ Leases ” and creates a new topic, ASC 842 “ Leases .” This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with earlier application permitted. This update will be applied using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the effect of this update on our consolidated financial statements. In January 2016, the FASB issued ASU 2016-01, "Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities ." The amendments in this update address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2017, and requires a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. Early adoption is not permitted. The new guidance will require the change in fair value of equity investments with readily determinable fair values to be recognized through the statement of income. We are currently evaluating the full impact of the standard; however, upon adoption, the change in the fair value of our available-for-sale equity investments will be recognized in our consolidated statement of income (loss) rather than as a component of our consolidated statement of comprehensive income (loss).

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying consolidated balance sheets: As of September 30, 2017 As of December 31, 2016 Fair Value Measurements: Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Marketable securities (see Note 4) Equity securities $ 454 $ — $ — $ 4,033 $ — $ — Money market funds 44,312 — — — — — Corporate bonds — 18,986 — — 57,348 — Government securities - U.S. — 11,133 — — 42,814 — Government securities - Non-U.S. — 69 — — 233 — Other fixed-income securities — 3,207 — — 10,471 — Other securities — — — — 81 — Total assets $ 44,766 $ 33,395 $ — $ 4,033 $ 110,947 $ — Related party payables (see Note 7) — — 107,117 — — 169,347 Total liabilities $ — $ — $ 107,117 $ — $ — $ 169,347

Marketable Securities (Tables)

Marketable Securities (Tables)	9 Months Ended
	Sep. 30, 2017
Investments, Debt and Equity Securities [Abstract]
Schedule of Available-for-sale Securities	The following tables show the Company’s available-for-sale securities’ adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of September 30, 2017 and December 31, 2016 , respectively: As of September 30, 2017 Marketable Securities: Adjusted Cost Unrealized Gains Unrealized Losses Fair Value Equity securities $ 438 $ 26 $ (10 ) $ 454 Money market funds 44,311 1 — 44,312 Corporate bonds 19,014 84 (112 ) 18,986 Government securities - U.S. 11,220 21 (108 ) 11,133 Government securities - Non-U.S. 70 — (1 ) 69 Other fixed-income securities 3,212 — (5 ) 3,207 Total $ 78,265 $ 132 $ (236 ) $ 78,161 As of December 31, 2016 Marketable Securities: Adjusted Cost Unrealized Gains Unrealized Losses Fair Value Equity securities $ 3,689 $ 409 $ (65 ) $ 4,033 Corporate bonds 57,871 89 (612 ) 57,348 Government securities - U.S. 43,049 515 (750 ) 42,814 Government securities - Non-U.S. 247 — (14 ) 233 Other fixed-income securities 10,281 221 (31 ) 10,471 Other securities 81 — — 81 Total $ 115,218 $ 1,234 $ (1,472 ) $ 114,980
Schedule of Contractual Maturity Dates	The following table summarizes the estimated fair value of our investments in marketable debt securities, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities as of September 30, 2017 : Maturities Marketable Debt Securities: Less than 1 Year 1-5 Years 5-10 Years Greater than 10 Years Total Corporate bonds 1,361 16,219 1,136 270 18,986 Government securities - U.S. 172 8,547 348 2,066 11,133 Government securities - Non-U.S. — — 69 — 69 Other fixed-income securities — 2,473 734 — 3,207 Total $ 1,533 $ 27,239 $ 2,287 $ 2,336 $ 33,395

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory	The principal categories of inventories, net of reserves of $2,039 and $3,223 at September 30, 2017 and December 31, 2016 , respectively, are comprised of the following: Inventory: September 30, 2017 December 31, 2016 Finished goods $ 4,605 $ 2,429 Raw materials 1,265 829 Total $ 5,870 $ 3,258

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The Company's amortizable and unamortizable intangible assets at September 30, 2017 and December 31, 2016 are as follows: As of September 30, 2017 As of December 31, 2016 Goodwill and Intangible Assets: Gross Value Accumulated Amortization Net Carrying Amount Gross Value Accumulated Amortization Net Carrying Amount Amortizable intangible assets: Acquired developed technology - Noctiva $ 73,111 $ — $ 73,111 $ — $ — $ — Acquired developed technology - Vazculep 12,061 (9,411 ) 2,650 12,061 (8,801 ) 3,260 Acquired product marketing rights 16,600 (1,854 ) 14,746 16,600 (1,019 ) 15,581 Acquired developed technology 4,300 (551 ) 3,749 4,300 (304 ) 3,996 Total amortizable intangible assets $ 106,072 $ (11,816 ) $ 94,256 $ 32,961 $ (10,124 ) $ 22,837 Unamortizable intangible assets: Goodwill $ 18,491 $ — $ 18,491 $ 18,491 $ — $ 18,491 Total unamortizable intangible assets $ 18,491 $ — $ 18,491 $ 18,491 $ — $ 18,491
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated amortization of intangible assets for the next five years is as follows: Estimated Amortization Expense: Amount 2017 $ 3,664 2018 7,882 2019 7,882 2020 7,882 2021 7,067

Long-Term Related Party Payab28

Long-Term Related Party Payable (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Schedule of Related Party Transactions	The following table summarizes changes to the related party payables, a recurring Level 3 measurement, for the nine -month periods ended September 30, 2017 and 2016 , respectively: Related Party Payable Rollforward: Balance Balance at December 31, 2015 $ 122,693 Additions (2) 22,695 Payment of related party payables (24,227 ) Fair value adjustments (1) 59,124 Balance at September 30, 2016 180,285 Balance at December 31, 2016 169,347 Payment of related party payable (29,135 ) Fair value adjustments (1) (33,095 ) Balance at September 30, 2017 $ 107,117 (1) Fair value adjustments are reported as Changes in fair value of related party contingent consideration and Other income (expense) - changes in fair value of related party payable in the Condensed Consolidated Statements of Income (Loss). (2) Relates to the acquisition of FSC. See items (c) and (f) above. Long-term related party payable and related activity are reported at fair value and consist of the following for the three months ended September 30, 2017 : Activity during the Three Months Ended September 30, 2017 Changes in Fair Value of Related Party Payable Long-Term Related Party Payable: Balance, June 30, 2017 Payments to Related Parties Operating Expense / (Income) Other Expense / (Income) Balance, September 30, 2017 Acquisition-related contingent consideration: Warrants - Éclat Pharmaceuticals (a) $ 10,400 $ — $ (2,173 ) $ — $ 8,227 Earn-out payments - Éclat Pharmaceuticals (b) 84,094 (8,214 ) (7,685 ) — 68,195 Royalty agreement - FSC (c) 8,010 (296 ) (48 ) — 7,666 Financing-related: Royalty agreement - Deerfield (d) 6,743 (784 ) — (520 ) 5,439 Royalty agreement - Broadfin (e) 3,212 (374 ) — (248 ) 2,590 Long-term liability - FSC (f) 15,000 — — — 15,000 Total related party payable 127,459 $ (9,668 ) $ (9,906 ) $ (768 ) 107,117 Less: Current portion (40,615 ) (30,986 ) Total long-term related party payable $ 86,844 $ 76,131 Long-term related party payable and related activity are reported at fair value and consist of the following for the nine months ended September 30, 2017 : Activity during the Nine Months Ended September 30, 2017 Changes in Fair Value of Related Party Payable Long-Term Related Party Payable: Balance, December 31, 2016 Payments to Related Parties Operating Expense / (Income) Other Expense / (Income) Balance, September 30, 2017 Acquisition-related contingent consideration: Warrants - Éclat Pharmaceuticals (a) $ 11,217 $ — $ (2,990 ) $ — $ 8,227 Earn-out payments - Éclat Pharmaceuticals (b) 121,377 (24,729 ) (28,453 ) — 68,195 Royalty agreement - FSC (c) 7,291 (961 ) 1,336 — 7,666 Financing-related: Royalty agreement - Deerfield (d) 9,794 (2,332 ) — (2,023 ) 5,439 Royalty agreement - Broadfin (e) 4,668 (1,113 ) — (965 ) 2,590 Long-term liability - FSC (f) 15,000 — — — 15,000 Total related party payable 169,347 $ (29,135 ) $ (30,107 ) $ (2,988 ) 107,117 Less: Current portion (34,177 ) (30,986 ) Total long-term related party payable $ 135,170 $ 76,131 (a) As part of the consideration for the Company’s acquisition of Éclat on March 13, 2012, the Company issued two warrants to a related party with a six -year term which allow for the purchase of a combined total of 3,300 ordinary shares of Avadel. One warrant is exercisable for 2,200 shares at an exercise price of $7.44 per share, and the other warrant is exercisable for 1,100 shares at an exercise price of $11.00 per share. The fair value of the warrants is estimated on a quarterly basis using a Black-Scholes option pricing model with the following assumptions as of September 30 : Assumptions for the Warrant Valuation: September 30, 2017 September 30, 2016 Stock price $ 10.50 $ 12.40 Weighted average exercise price per share 8.63 8.63 Expected term (years) 0.50 1.50 Expected volatility 40.30 % 58.40 % Risk-free interest rate 1.20 % 0.68 % Expected dividend yield — — These Black-Scholes fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. The fair value of the warrant consideration is most sensitive to movement in the Company’s share price and expected volatility at the balance sheet date. Expected term : The expected term of the options or warrants represents the period of time between the grant date and the time the options or warrants are either exercised or forfeited, including an estimate of future forfeitures for outstanding options or warrants. Given the limited historical data and the grant of stock options and warrants to a limited population, the simplified method has been used to calculate the expected life. Expected volatility : The expected volatility is calculated based on an average of the historical volatility of the Company's stock price. Risk-free interest rate : The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant and a maturity that approximates the expected term. Expected dividend yield : The Company has not distributed any dividends since our inception and has no plan to distribute dividends in the foreseeable future. At the closing date of the 2012 Éclat acquisition and at September 30, 2017 , it was uncertain as to whether the Company would ultimately fulfill our obligation under these warrants using Company shares or cash. Accordingly, pursuant to the guidance of ASC 480, the Company determined that these warrants should be classified as a liability. This classification as a liability was further supported by the Company’s determination, pursuant to the guidance of ASC 815-40-15-7(i), that these warrants could also not be considered as being indexed to the Company’s own stock, on the basis that the exercise price for the warrants is determined in U.S. dollars, although the functional currency of the Company at the closing date of the Éclat acquisition was the Euro. (b) In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by the Company’s CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity. (c) In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part included a commitment to pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years. (d) As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat products until December 31, 2024. In connection with such debt financing transaction, the Company granted Deerfield a security interest in the product registration rights of the Eclat products. (e) As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat products until December 31, 2024. (f) In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part consists of payments totaling $1,050 annually for five years with a final payment in January 2021 of $15,000 . Substantially all of FSC's, and its subsidiaries, assets are pledged as collateral under this agreement.

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Schedule of Components of Income Before Income Tax	The components of income (loss) before income taxes are as follows: Three Months Ended September 30, Nine Months Ended September 30, Income (Loss) Before Income Taxes: 2017 2016 2017 2016 Ireland $ (6,111 ) $ (3,485 ) $ 1,924 $ (17,413 ) United States 29,627 (6,814 ) 96,288 4,948 France 3,313 (6,244 ) (1,950 ) (15,333 ) Other 771 — 2,084 — Total income before income taxes $ 27,600 $ (16,543 ) $ 98,346 $ (27,798 )
Schedule of Effective Income Tax Rate Reconciliation	The items accounting for the difference between the income tax provision computed at the statutory rate and the Company's effective tax rate are as follows: Three Months Ended September 30, Nine Months Ended September 30, Income Tax Rate Reconciliation: 2017 2016 2017 2016 Statutory tax rate 12.5 % 33.3 % 12.5 % 33.3 % International tax rates differential 24.9 % (3.6 )% 20.5 % (13.3 )% Valuation allowance on net operating loss (1.6 )% (2.0 )% 0.5 % (15.3 )% Nondeductible change in fair value of contingent consideration (12.8 )% (38.9 )% (10.9 )% (62.0 )% Other (1.6 )% (9.6 )% (0.3 )% (8.2 )% Effective income tax rate 21.4 % (20.8 )% 22.3 % (65.5 )% Income tax provision - at statutory tax rate $ 3,449 $ (5,509 ) $ 12,294 $ (9,257 ) International tax rates differential 6,861 591 20,120 3,706 Valuation allowance on net operating loss (438 ) 339 476 4,252 Nondeductible change in fair value of contingent consideration (3,521 ) 6,436 (10,751 ) 17,236 Other (430 ) 1,594 (309 ) 2,275 Income tax provision - at effective income tax rate $ 5,921 $ 3,451 $ 21,830 $ 18,212

Other Assets and Liabilities (T

Other Assets and Liabilities (Tables)	9 Months Ended
	Sep. 30, 2017
Other Liabilities Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Various other assets and liabilities are summarized as follows: Prepaid Expenses and Other Current Assets: September 30, 2017 December 31, 2016 Valued-added tax recoverable $ 1,049 $ 736 Prepaid expenses 1,002 3,442 Advance to suppliers and other current assets 726 1,265 Income tax receivable 596 451 Total $ 3,373 $ 5,894
Schedule of Other Assets, Noncurrent	Other Non-Current Assets: September 30, 2017 December 31, 2016 Deferred tax assets $ 7,110 $ 7,432 Other 1,910 99 Total $ 9,020 $ 7,531
Schedule of Accrued Liabilities	Accrued Expenses: September 30, 2017 December 31, 2016 Accrued compensation $ 3,456 $ 3,291 Accrued social charges 827 794 Accrued employee severance (see Note 10) 1,926 — Customer allowances 13,453 7,981 Accrued amounts due to contract research organization 1,472 1,764 Accrued ELAA payment 20,000 — Accrued CMO charges 2,380 936 Other 4,483 2,456 Total $ 47,997 $ 17,222
Schedule Of Long Term Liabilities	Other Non-Current Liabilities: September 30, 2017 December 31, 2016 Provision for retirement indemnity $ 2,137 $ 2,431 Customer allowances 1,883 905 Unrecognized tax benefits 2,456 1,565 Other 435 374 Total $ 6,911 $ 5,275

Restructuring Costs (Tables)

Restructuring Costs (Tables)	9 Months Ended
	Sep. 30, 2017
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Related Costs	The following table sets forth activities for the Company’s cost reduction plan obligations for the nine months ended September 30, 2017 . There were no restructuring related charges in the nine months ended September 30, 2016 : Severance Obligation: 2017 Balance of accrued costs at January 1, $ — Charges for employee severance, benefits and other 3,722 Payments (2,164 ) Foreign currency impact 368 Balance of accrued costs at September 30, $ 1,926

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Schedule of Earnings Per Share Reconciliation	A reconciliation of basic and diluted net income (loss) per share, together with the related shares outstanding in thousands is as follows: Three Months Ended September 30, Nine Months Ended September 30, Net Income (Loss) Per Share: 2017 2016 2017 2016 Net income (loss) $ 21,679 $ (19,994 ) $ 76,516 $ (46,010 ) Weighted average shares: Basic shares 40,061 41,241 40,839 41,241 Effect of dilutive securities—options and warrants outstanding 1,278 — 1,355 — Diluted shares 41,339 41,241 42,194 41,241 Net income (loss) per share - basic $ 0.54 $ (0.48 ) $ 1.87 $ (1.12 ) Net income (loss) per share - diluted $ 0.52 $ (0.48 ) $ 1.81 $ (1.12 )

Comprehensive Income (Loss) (Ta

Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2017
Stockholders' Equity Note [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	The following table shows the components of accumulated other comprehensive loss for the three and nine months ended September 30, 2017 and 2016 , respectively, net of tax effects: Three Months Ended September 30, Nine Months Ended September 30, Accumulated Other Comprehensive Loss: 2017 2016 2017 2016 Foreign currency translation adjustment: Beginning balance $ (23,089 ) $ (19,952 ) $ (23,336 ) $ (22,312 ) Foreign currency translation gain (loss) (229 ) 1,567 18 3,927 Balance at September 30, $ (23,318 ) $ (18,385 ) $ (23,318 ) $ (18,385 ) Unrealized gain (loss) on marketable securities, net Beginning balance $ 409 $ 1,102 $ (229 ) $ (345 ) Net other comprehensive income (loss), net of $92, $152, $0 and ($49) tax, respectively (512 ) (2,405 ) 126 (958 ) Balance at September 30, $ (103 ) $ (1,303 ) $ (103 ) $ (1,303 ) Accumulated other comprehensive loss at September 30, $ (23,421 ) $ (19,688 ) $ (23,421 ) $ (19,688 )

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2017
Stockholders' Equity Note [Abstract]
Schedule of Stockholders Equity	The following table presents a reconciliation of the Company’s beginning and ending balances in shareholders’ equity for the nine months ended September 30, 2017 : Shareholders' Equity: 2017 Shareholders' equity - January 1, $ 42,069 Net income 76,516 Adjustment to accumulated deficit (see Note 2) (11,156 ) Other comprehensive income 144 Stock option exercised 377 Stock-based compensation expense 6,019 Share repurchases (17,506 ) Shareholders' equity - September 30, $ 96,463

Company Operations by Product (

Company Operations by Product (Tables)	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, Revenue by Product	The following table presents a summary of total revenues by these products: Three Months Ended September 30, Nine Months Ended September 30, Revenues by Product: 2017 2016 2017 2016 Bloxiverz $ 9,920 $ 15,591 $ 37,541 $ 65,958 Vazculep 9,573 9,340 29,906 29,167 Akovaz 18,561 5,568 65,110 5,568 Other 1,093 841 5,452 4,165 Total product sales and services 39,147 31,340 138,009 104,858 License and research revenue 528 747 484 2,303 Total revenues $ 39,675 $ 32,087 $ 138,493 $ 107,161

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Purchase Commitment Schedule	The Company has a commitment to purchase finished product from a contract manufacturer for a six-year period commencing in 2018. Commitments for this arrangement, at maximum quantities and at contractual prices over the remaining life of the contract, and excluding any waived commitments, are as follows for the years ended December 31: Purchase Commitment: Balance 2018 $ 3,241 2019 3,704 2020 3,704 2021 3,704 2022 3,704 Thereafter 3,704 Total $ 21,761

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Merger Agreement (Details)	Dec. 31, 2016USD ($)$ / sharesshares	Sep. 30, 2017$ / sharesshares	Mar. 06, 2017USD ($)	Dec. 30, 2016€ / shares
Class of Stock [Line Items]
Authorized share capital	$ 5,500,000
Ordinary shares, shares authorized (in shares) | shares	500,000,000	500,000,000
Ordinary shares, nominal value (in usd per share) | (per share)	$ 0.01	$ 0.01		€ 0.122
Preferred shares, shares authorized (in shares) | shares	50,000,000	50,000,000
Preferred shares, nominal value (in usd per share) | $ / shares	$ 0.01	$ 0.01
Adjustment to reduce share premium			$ 317,254,000
Adjustment to increase available distributable reserves			$ 317,254,000
Ordinary shares
Class of Stock [Line Items]
Adjustment to nominal value upon merger	$ (5,937,000)
Additional Paid-in Capital
Class of Stock [Line Items]
Adjustment to nominal value upon merger	$ 5,937,000

Newly Issued Accounting Prono38

Newly Issued Accounting Pronouncements - Recently Adopted (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Adjustment to accumulated deficit	$ (11,156)
ASU 2016-16 | Early Adoption, Effect
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Elimination of income tax deferred charge		$ 11,156
Accumulated deficit | ASU 2016-16 | Early Adoption, Effect
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Adjustment to accumulated deficit		$ (11,156)

Fair Value Measurement - Measur

Fair Value Measurement - Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)	$ 78,161	$ 114,980
Equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)	454	4,033
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)	44,312
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)	18,986	57,348
Government securities - U.S.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)	11,133	42,814
Government securities - Non-U.S.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)	69	233
Other fixed-income securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)	3,207	10,471
Other securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)		81
Level 1 | Equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)	454	4,033
Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)	44,312
Level 2 | Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)	18,986	57,348
Level 2 | Government securities - U.S.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)	11,133	42,814
Level 2 | Government securities - Non-U.S.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)	69	233
Level 2 | Other fixed-income securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)	3,207	10,471
Level 2 | Other securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)		81
Fair Value Measurements, Recurring | Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	44,766	4,033
Fair Value Measurements, Recurring | Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	33,395	110,947
Fair Value Measurements, Recurring | Level 2 | Other securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable securities (see Note 4)	0
Fair Value Measurements, Recurring | Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Related party payables (see Note 7)	107,117	169,347
Total liabilities	$ 107,117	$ 169,347

Marketable Securities - Narrati

Marketable Securities - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Investments, Debt and Equity Securities [Abstract]
Gross realized gains	$ 2,978	$ 635	$ 4,228	$ 709
Gross realized losses	$ 2,432	$ 756	$ 3,755	$ 1,430

Marketable Securities - Summary

Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	$ 78,265	$ 115,218
Unrealized Gains	132	1,234
Unrealized Losses	(236)	(1,472)
Fair Value	78,161	114,980
Equity securities
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	438	3,689
Unrealized Gains	26	409
Unrealized Losses	(10)	(65)
Fair Value	454	4,033
Money market funds
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	44,311
Unrealized Gains	1
Unrealized Losses	0
Fair Value	44,312
Corporate bonds
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	19,014	57,871
Unrealized Gains	84	89
Unrealized Losses	(112)	(612)
Fair Value	18,986	57,348
Government securities - U.S.
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	11,220	43,049
Unrealized Gains	21	515
Unrealized Losses	(108)	(750)
Fair Value	11,133	42,814
Government securities - Non-U.S.
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	70	247
Unrealized Gains	0	0
Unrealized Losses	(1)	(14)
Fair Value	69	233
Other fixed-income securities
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost	3,212	10,281
Unrealized Gains	0	221
Unrealized Losses	(5)	(31)
Fair Value	$ 3,207	10,471
Other securities
Schedule of Available-for-sale Securities [Line Items]
Adjusted Cost		81
Unrealized Gains		0
Unrealized Losses		0
Fair Value		$ 81

Marketable Securities - Schedul

Marketable Securities - Schedule of Maturities (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Schedule of Available-for-sale Securities [Line Items]
Fair Value	$ 78,161	$ 114,980
Corporate bonds
Schedule of Available-for-sale Securities [Line Items]
Less than 1 Year	1,361
1-5 Years	16,219
5-10 Years	1,136
Greater than 10 Years	270
Fair Value	18,986	57,348
Government securities - U.S.
Schedule of Available-for-sale Securities [Line Items]
Less than 1 Year	172
1-5 Years	8,547
5-10 Years	348
Greater than 10 Years	2,066
Fair Value	11,133	42,814
Government securities - Non-U.S.
Schedule of Available-for-sale Securities [Line Items]
Less than 1 Year	0
1-5 Years	0
5-10 Years	69
Greater than 10 Years	0
Fair Value	69	233
Other fixed-income securities
Schedule of Available-for-sale Securities [Line Items]
Less than 1 Year	0
1-5 Years	2,473
5-10 Years	734
Greater than 10 Years	0
Fair Value	3,207	$ 10,471
Total debt securities
Schedule of Available-for-sale Securities [Line Items]
Less than 1 Year	1,533
1-5 Years	27,239
5-10 Years	2,287
Greater than 10 Years	2,336
Fair Value	$ 33,395

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventory reserves	$ 2,039	$ 3,223
Inventory:
Finished goods	4,605	2,429
Raw materials	1,265	829
Total	$ 5,870	$ 3,258

Goodwill and Intangible Asset44

Goodwill and Intangible Assets - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Intangible asset amortization	$ 564	$ 3,702	$ 1,692	$ 10,918
Upfront payment for developed technology			52,139	$ 0
Accrued ELAA payment	20,000		20,000		$ 0
Transaction costs	3,111		$ 3,111
Amortization period (in years)			13 years
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)			3 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)			15 years
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Developed technology acquired			$ 73,111
Upfront payment for developed technology			50,000
Accrued ELAA payment	$ 20,000		$ 20,000

Goodwill and Intangible Asset45

Goodwill and Intangible Assets - Gross Value and Net Carrying Amount (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Amortizable intangible assets:
Gross Value	$ 106,072	$ 32,961
Accumulated Amortization	(11,816)	(10,124)
Net Carrying Amount	94,256	22,837
Unamortizable intangible assets:
Gross Value	18,491	18,491
Net Carrying Amount	18,491	18,491
Developed technology
Amortizable intangible assets:
Gross Value	4,300	4,300
Accumulated Amortization	(551)	(304)
Net Carrying Amount	3,749	3,996
Developed technology | Noctiva
Amortizable intangible assets:
Gross Value	73,111	0
Accumulated Amortization	0	0
Net Carrying Amount	73,111	0
Developed technology | Vazculep
Amortizable intangible assets:
Gross Value	12,061	12,061
Accumulated Amortization	(9,411)	(8,801)
Net Carrying Amount	2,650	3,260
Product marketing rights
Amortizable intangible assets:
Gross Value	16,600	16,600
Accumulated Amortization	(1,854)	(1,019)
Net Carrying Amount	$ 14,746	$ 15,581

Goodwill and Intangible Asset46

Goodwill and Intangible Assets - Estimated Future Amortization (Details) $ in Thousands	Sep. 30, 2017USD ($)
Estimated Amortization Expense:
2,017	$ 3,664
2,018	7,882
2,019	7,882
2,020	7,882
2,021	$ 7,067

Long-Term Related Party Payab47

Long-Term Related Party Payable - Narrative (Details) - USD ($)	Feb. 05, 2016	Mar. 13, 2012	Feb. 28, 2016	Dec. 31, 2013	Feb. 28, 2013	Mar. 31, 2012	Jan. 31, 2021	Sep. 30, 2017
Minimum
Line of Credit Facility [Line Items]
Discounted cash flow risk adjusted discount rate								15.00%
Maximum
Line of Credit Facility [Line Items]
Discounted cash flow risk adjusted discount rate								22.00%
Broadfin Debt Financing
Line of Credit Facility [Line Items]
Percentage of royalty payable on net sales				0.834%
Cash consideration received on royalty agreement				$ 2,200,000
Affiliated Entity | Deerfield FSC LLC
Line of Credit Facility [Line Items]
Percentage of royalty payable on net sales					1.75%
Cash consideration received on royalty agreement					$ 2,600,000
Eclat Pharmaceuticals
Line of Credit Facility [Line Items]
Warrants issued (in shares)		2
Warrant term		6 years
Number of securities called by warrants (in shares)		3,300,000
Percentage of earn-out payments						20.00%
Eclat Pharmaceuticals | Exercise Price 1
Line of Credit Facility [Line Items]
Number of securities called by each warrant (in shares)		2,200,000
Exercise price of warrants (in dollars per share)		$ 7.44
Eclat Pharmaceuticals | Exercise Price 2
Line of Credit Facility [Line Items]
Number of securities called by each warrant (in shares)		1,100,000
Exercise price of warrants (in dollars per share)		$ 11
FSC Holdings, LLC | Affiliated Entity | Deerfield FSC LLC
Line of Credit Facility [Line Items]
Percentage of royalty payable on net sales	15.00%
Debt instrument, periodic payment			$ 1,050,000
Debt instrument, term (in years)			5 years
FSC Holdings, LLC | Affiliated Entity | Deerfield FSC LLC | Scenario, Forecast
Line of Credit Facility [Line Items]
Debt instrument, final payment amount							$ 15,000,000
FSC Holdings, LLC | Affiliated Entity | Deerfield FSC LLC | Maximum
Line of Credit Facility [Line Items]
Royalty amount	$ 12,500,000
Royalty guarantees, commitments, term (in years)	10 years

Long-Term Related Party Payab48

Long-Term Related Party Payable - Activity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017	Dec. 31, 2016
Acquisition-related contingent consideration:
Related party payable, beginning balance	$ 127,459		$ 169,347	$ 122,693
Additions				22,695
Payments to Related Parties	(9,668)		(29,135)	(24,227)
Changes in fair value of related party payable operating expense (income)	(9,906)	$ 20,848	(30,107)	52,989
Changes in fair value of related party payable other expense (income)	(768)		(2,988)
Related party payable, ending balance	107,117	$ 180,285	107,117	$ 180,285
Less: Current portion	(30,986)		(30,986)		$ (40,615)	$ (34,177)
Long-term related party payable	76,131		76,131		$ 86,844	$ 135,170
Acquisition-related contingent consideration: | Earn-out payments
Acquisition-related contingent consideration:
Related party payable, beginning balance	84,094		121,377
Payments to Related Parties	(8,214)		(24,729)
Changes in fair value of related party payable operating expense (income)	(7,685)		(28,453)
Changes in fair value of related party payable other expense (income)	0		0
Related party payable, ending balance	68,195		68,195
Acquisition-related contingent consideration: | Royalty agreement - FSC
Acquisition-related contingent consideration:
Related party payable, beginning balance	8,010		7,291
Payments to Related Parties	(296)		(961)
Changes in fair value of related party payable operating expense (income)	(48)		1,336
Changes in fair value of related party payable other expense (income)	0		0
Related party payable, ending balance	7,666		7,666
Acquisition-related contingent consideration: | Warrants
Acquisition-related contingent consideration:
Related party payable, beginning balance	10,400		11,217
Payments to Related Parties	0		0
Changes in fair value of related party payable operating expense (income)	(2,173)		(2,990)
Changes in fair value of related party payable other expense (income)	0		0
Related party payable, ending balance	8,227		8,227
Financing-related:
Acquisition-related contingent consideration:
Related party payable, beginning balance	15,000		15,000
Payments to Related Parties	0		0
Changes in fair value of related party payable operating expense (income)	0		0
Changes in fair value of related party payable other expense (income)	0		0
Related party payable, ending balance	15,000		15,000
Financing-related: | Royalty agreement - Deerfield
Acquisition-related contingent consideration:
Related party payable, beginning balance	6,743		9,794
Payments to Related Parties	(784)		(2,332)
Changes in fair value of related party payable operating expense (income)	0		0
Changes in fair value of related party payable other expense (income)	(520)		(2,023)
Related party payable, ending balance	5,439		5,439
Financing-related: | Royalty agreement - Broadfin
Acquisition-related contingent consideration:
Related party payable, beginning balance	3,212		4,668
Payments to Related Parties	(374)		(1,113)
Changes in fair value of related party payable operating expense (income)	0		0
Changes in fair value of related party payable other expense (income)	(248)		(965)
Related party payable, ending balance	$ 2,590		$ 2,590

Long-Term Related Party Payab49

Long-Term Related Party Payable - Warrant Fair Value Assumptions (Details) - Warrants - $ / shares	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Schedule of Capitalization, Long-term Debt [Line Items]
Stock price (in dollars per share)	$ 10.50	$ 12.40
Weighted average exercise price per share (in dollars per share)	$ 8.63	$ 8.63
Expected term (years)	6 months	1 year 6 months
Expected volatility	40.30%	58.40%
Risk-free interest rate	1.20%	0.68%
Expected dividend yield	0.00%	0.00%

Long-Term Related Party Payab50

Long-Term Related Party Payable Long-Term Related Party Payable - Payable Balance (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2017	Sep. 30, 2016
Related Party Payable Rollforward:
Related party payable, beginning balance	$ 127,459	$ 169,347	$ 122,693
Additions			22,695
Payment of related party payable	(9,668)	(29,135)	(24,227)
Fair value adjustments		(33,095)	59,124
Related party payable, ending balance	$ 107,117	$ 107,117	$ 180,285

Income Taxes - Income (Loss) Be

Income Taxes - Income (Loss) Before Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Taxes [Line Items]
Total income before income taxes	$ 27,600	$ (16,543)	$ 98,346	$ (27,798)
Ireland
Income Taxes [Line Items]
Total income before income taxes	(6,111)	(3,485)	1,924	(17,413)
United States
Income Taxes [Line Items]
Total income before income taxes	29,627	(6,814)	96,288	4,948
France
Income Taxes [Line Items]
Total income before income taxes	3,313	(6,244)	(1,950)	(15,333)
Other
Income Taxes [Line Items]
Total income before income taxes	$ 771	$ 0	$ 2,084	$ 0

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Tax Rate (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory tax rate	12.50%	33.30%	12.50%	33.30%
International tax rates differential	24.90%	(3.60%)	20.50%	(13.30%)
Valuation allowance on net operating loss	(1.60%)	(2.00%)	0.50%	(15.30%)
Nondeductible change in fair value of contingent consideration	(12.80%)	(38.90%)	(10.90%)	(62.00%)
Other	(1.60%)	(9.60%)	(0.30%)	(8.20%)
Effective income tax rate	21.40%	(20.80%)	22.30%	(65.50%)
Effective Income Tax Rate Reconciliation, Amount [Abstract]
Income tax provision - at statutory tax rate	$ 3,449	$ (5,509)	$ 12,294	$ (9,257)
International tax rates differential	6,861	591	20,120	3,706
Valuation allowance on net operating loss	(438)	339	476	4,252
Nondeductible change in fair value of contingent consideration	(3,521)	6,436	(10,751)	17,236
Other	(430)	1,594	(309)	2,275
Income tax provision - at effective income tax rate	$ 5,921	$ 3,451	$ 21,830	$ 18,212

Other Assets and Liabilities -

Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Prepaid Expenses and Other Current Assets:
Valued-added tax recoverable	$ 1,049	$ 736
Prepaid expenses	1,002	3,442
Advance to suppliers and other current assets	726	1,265
Income tax receivable	596	451
Total	$ 3,373	$ 5,894

Other Assets and Liabilities 54

Other Assets and Liabilities - Other Non-Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Other Non-Current Assets:
Deferred tax assets	$ 7,110	$ 7,432
Other	1,910	99
Total	$ 9,020	$ 7,531

Other Assets and Liabilities 55

Other Assets and Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Accrued Expenses:
Accrued compensation	$ 3,456	$ 3,291
Accrued social charges	827	794
Accrued employee severance (see Note 10)	1,926	0
Customer allowances	13,453	7,981
Accrued amounts due to contract research organization	1,472	1,764
Accrued ELAA payment	20,000	0
Accrued CMO charges	2,380	936
Other	4,483	2,456
Total	$ 47,997	$ 17,222

Other Assets and Liabilities 56

Other Assets and Liabilities - Other Non-Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Other Non-Current Liabilities:
Provision for retirement indemnity	$ 2,137	$ 2,431
Customer allowances	1,883	905
Unrecognized tax benefits	2,456	1,565
Other	435	374
Total	$ 6,911	$ 5,275

Restructuring Costs - Narrative

Restructuring Costs - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring (income) costs	$ (549)	$ 0	$ 3,173	$ 0
Curtailment gain	549
Employee Severance | Lyon France Workforce Reduction
Restructuring Cost and Reserve [Line Items]
Expected number of positions eliminated (as a percent)					50.00%
Restructuring and related cost, expected cost	$ 500		$ 500

Restructuring Costs - Severance

Restructuring Costs - Severance Obligation (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance	$ 0
Charges for employee severance, benefits and other	3,722
Payments	(2,164)
Foreign currency impact	368
Restructuring reserve, ending balance	$ 1,926

Net Income (Loss) Per Share - N

Net Income (Loss) Per Share - Narrative (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	5,008	6,860	5,086	6,860

Net Income (Loss) Per Share - R

Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Calculation (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Net income (loss)	$ 21,679	$ (19,994)	$ 76,516	$ (46,010)
Weighted average shares:
Basic shares (in shares)	40,061	41,241	40,839	41,241
Effect of dilutive securities—options and warrants outstanding (in shares)	1,278	0	1,355	0
Diluted shares (in shares)	41,339	41,241	42,194	41,241
Net income (loss) per share - basic (in dollars per share)	$ 0.54	$ (0.48)	$ 1.87	$ (1.12)
Net income (loss) per share - diluted (in dollars per share)	$ 0.52	$ (0.48)	$ 1.81	$ (1.12)

Comprehensive Income (Loss) (De

Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Accumulated Other Comprehensive Loss:
Beginning balance			$ 42,069
Net other comprehensive income, foreign currency translation adjustment	$ (229)	$ 1,567	18	$ 3,927
Net other comprehensive income, unrealized gain (loss) on marketable securities, net	(512)	(2,405)	126	(958)
Ending balance	96,463		96,463
Unrealized gain (loss) on marketable securities, tax	92	152	0	(49)
Foreign currency translation adjustment:
Accumulated Other Comprehensive Loss:
Beginning balance	(23,089)	(19,952)	(23,336)	(22,312)
Net other comprehensive income, foreign currency translation adjustment	(229)	1,567	18	3,927
Ending balance	(23,318)	(18,385)	(23,318)	(18,385)
Unrealized gain (loss) on marketable securities, net
Accumulated Other Comprehensive Loss:
Beginning balance	409	1,102	(229)	(345)
Net other comprehensive income, unrealized gain (loss) on marketable securities, net	(512)	(2,405)	126	(958)
Ending balance	(103)	(1,303)	(103)	(1,303)
Accumulated Other Comprehensive Loss:
Accumulated Other Comprehensive Loss:
Ending balance	$ (23,421)	$ (19,688)	$ (23,421)	$ (19,688)

Shareholders' Equity - Reconcil

Shareholders' Equity - Reconciliation of Shareholders' Equity (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Shareholders' Equity:
Beginning balance			$ 42,069
Net income	$ 21,679	$ (19,994)	76,516	$ (46,010)
Adjustment to accumulated deficit (see Note 2)	(11,156)		(11,156)
Other comprehensive income	(741)	$ (838)	144	$ 2,969
Stock option exercised			377
Stock-based compensation expense			6,019
Share repurchases			(17,506)
Ending balance	$ 96,463		$ 96,463

Shareholders' Equity - Narrativ

Shareholders' Equity - Narrative (Details) - USD ($)	9 Months Ended
	Sep. 30, 2017	Mar. 31, 2017
Class of Stock [Line Items]
Shares value authorized to be repurchased		$ 25,000,000
Shares authorized to repurchase	1,673,000
Share repurchases	$ 17,506,000
Treasury Stock
Class of Stock [Line Items]
Unsettled repurchases of stock in accounts payable	$ 799,000

Company Operations by Product -

Company Operations by Product - Narrative (Details)	9 Months Ended
	Sep. 30, 2017segment
Segment Reporting [Abstract]
Number of operating segments (in segments)	1

Company Operations by Product65

Company Operations by Product - Summary of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Total product sales and services	$ 39,147	$ 31,340	$ 138,009	$ 104,858
License and research revenue	528	747	484	2,303
Total	39,675	32,087	138,493	107,161
Bloxiverz
Segment Reporting Information [Line Items]
Total product sales and services	9,920	15,591	37,541	65,958
Vazculep
Segment Reporting Information [Line Items]
Total product sales and services	9,573	9,340	29,906	29,167
Akovaz
Segment Reporting Information [Line Items]
Total product sales and services	18,561	5,568	65,110	5,568
Other
Segment Reporting Information [Line Items]
Total product sales and services	$ 1,093	$ 841	$ 5,452	$ 4,165

Commitments and Contingencies -

Commitments and Contingencies - Purchase Commitment (Details) $ in Thousands	Sep. 30, 2017USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,018	$ 3,241
2,019	3,704
2,020	3,704
2,021	3,704
2,022	3,704
Thereafter	3,704
Total	$ 21,761